These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 20086037)

  • 1. Multiple affinity states of cGMP-specific phosphodiesterase for sildenafil inhibition defined by cGMP-dependent and cGMP-independent mechanisms.
    Rybalkina IG; Tang XB; Rybalkin SD
    Mol Pharmacol; 2010 Apr; 77(4):670-7. PubMed ID: 20086037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization.
    Blount MA; Zoraghi R; Ke H; Bessay EP; Corbin JD; Francis SH
    Mol Pharmacol; 2006 Nov; 70(5):1822-31. PubMed ID: 16926278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conversion of phosphodiesterase-5 (PDE5) catalytic site to higher affinity by PDE5 inhibitors.
    Blount MA; Zoraghi R; Bessay EP; Beasley A; Francis SH; Corbin JD
    J Pharmacol Exp Ther; 2007 Nov; 323(2):730-7. PubMed ID: 17690252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [3H]sildenafil binding to phosphodiesterase-5 is specific, kinetically heterogeneous, and stimulated by cGMP.
    Corbin JD; Blount MA; Weeks JL; Beasley A; Kuhn KP; Ho YS; Saidi LF; Hurley JH; Kotera J; Francis SH
    Mol Pharmacol; 2003 Jun; 63(6):1364-72. PubMed ID: 12761347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation.
    Blount MA; Beasley A; Zoraghi R; Sekhar KR; Bessay EP; Francis SH; Corbin JD
    Mol Pharmacol; 2004 Jul; 66(1):144-52. PubMed ID: 15213306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The GAF domain of the cGMP-binding, cGMP-specific phosphodiesterase (PDE5) is a sensor and a sink for cGMP.
    Biswas KH; Sopory S; Visweswariah SS
    Biochemistry; 2008 Mar; 47(11):3534-43. PubMed ID: 18293931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sildenafil treatment in vivo stimulates Leydig cell steroidogenesis via the cAMP/cGMP signaling pathway.
    Andric SA; Janjic MM; Stojkov NJ; Kostic TS
    Am J Physiol Endocrinol Metab; 2010 Oct; 299(4):E544-50. PubMed ID: 20663985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphodiesterase 5 inhibitors prevent 3,4-methylenedioxymethamphetamine-induced 5-HT deficits in the rat.
    Puerta E; Hervias I; Goñi-Allo B; Lasheras B; Jordan J; Aguirre N
    J Neurochem; 2009 Feb; 108(3):755-66. PubMed ID: 19187094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sildenafil promotes adipogenesis through a PKG pathway.
    Zhang X; Ji J; Yan G; Wu J; Sun X; Shen J; Jiang H; Wang H
    Biochem Biophys Res Commun; 2010 Jun; 396(4):1054-9. PubMed ID: 20471953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of Sildenafil on human platelet secretory function is controlled by a complex interplay between phosphodiesterases 2, 3 and 5.
    Dunkern TR; Hatzelmann A
    Cell Signal; 2005 Mar; 17(3):331-9. PubMed ID: 15567064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conformational conversion of PDE5 by incubation with sildenafil or metal ion is accompanied by stimulation of allosteric cGMP binding.
    Corbin JD; Francis SH
    Cell Signal; 2011 Oct; 23(10):1578-83. PubMed ID: 21620965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Critical amino acids in phosphodiesterase-5 catalytic site that provide for high-affinity interaction with cyclic guanosine monophosphate and inhibitors.
    Zoraghi R; Francis SH; Corbin JD
    Biochemistry; 2007 Nov; 46(47):13554-63. PubMed ID: 17979301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PDE5 is converted to an activated state upon cGMP binding to the GAF A domain.
    Rybalkin SD; Rybalkina IG; Shimizu-Albergine M; Tang XB; Beavo JA
    EMBO J; 2003 Feb; 22(3):469-78. PubMed ID: 12554648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metal ion stimulators of PDE5 cause similar conformational changes in the enzyme as does cGMP or sildenafil.
    Corbin JD; Foster TL; Bessay E; Busch J; Blount M; Francis SH
    Cell Signal; 2011 May; 23(5):778-84. PubMed ID: 21187142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of cGMP in sildenafil-induced activation of endothelial Ca2+-activated K+ channels.
    Luedders DW; Muenz BM; Li F; Rueckleben S; Tillmanns H; Waldecker B; Wiecha J; Erdogan A; Schaefer CA; Kuhlmann CR
    J Cardiovasc Pharmacol; 2006 Mar; 47(3):365-70. PubMed ID: 16633077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The phosphodiesterase 5 inhibitor sildenafil stimulates angiogenesis through a protein kinase G/MAPK pathway.
    Pyriochou A; Zhou Z; Koika V; Petrou C; Cordopatis P; Sessa WC; Papapetropoulos A
    J Cell Physiol; 2007 Apr; 211(1):197-204. PubMed ID: 17226792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compartmentalization of cardiac beta-adrenergic inotropy modulation by phosphodiesterase type 5.
    Takimoto E; Belardi D; Tocchetti CG; Vahebi S; Cormaci G; Ketner EA; Moens AL; Champion HC; Kass DA
    Circulation; 2007 Apr; 115(16):2159-67. PubMed ID: 17420342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Celecoxib dilates guinea-pig coronaries and rat aortic rings and amplifies NO/cGMP signaling by PDE5 inhibition.
    Klein T; Eltze M; Grebe T; Hatzelmann A; Kömhoff M
    Cardiovasc Res; 2007 Jul; 75(2):390-7. PubMed ID: 17383621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct allostery induced in the cyclic GMP-binding, cyclic GMP-specific phosphodiesterase (PDE5) by cyclic GMP, sildenafil, and metal ions.
    Biswas KH; Visweswariah SS
    J Biol Chem; 2011 Mar; 286(10):8545-8554. PubMed ID: 21193396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigating the role of protein kinase-G in the antidepressant-like response of sildenafil in combination with muscarinic acetylcholine receptor antagonism.
    Liebenberg N; Wegener G; Harvey BH; Brink CB
    Behav Brain Res; 2010 May; 209(1):137-41. PubMed ID: 20117144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.